Brief: Chemomab Therapeutics Reports Positive Data From Secondary Analysis Of Phase 2A Liver Fibrosis Trial In NASH Patients At EASL 2023
21/06/2023 12:14
June 21 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS REPORTS POSITIVE DATA FROM SECONDARY
ANALYSIS OF PHASE 2A LIVER FIBROSIS TRIAL IN NASH PATIENTS AT
EASL 2023
* CHEMOMAB THERAPEUTICS REPORTS POSITIVE DATA FROM SECONDARY
ANALYSIS OF PHASE 2A LIVER FIBROSIS TRIAL IN NASH PATIENTS AT
EASL 2023
* CHEMOMAB : TREATMENT WITH CM-101 IMPROVES ADDITIONAL
BIOMARKERS
OF FIBROSIS AND INFLAMMATION, `REINFORCING AND EXTENDING INITIAL
STUDY RESULTS
Source text for Eikon: ID:nPnbPG2Hga
Further company coverage: CMMB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update